Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
Top Cited Papers
- 1 April 2014
- journal article
- conference paper
- Published by Elsevier BV in Journal of the American Society of Hypertension
- Vol. 8 (4), 262-275.e9
- https://doi.org/10.1016/j.jash.2014.01.007
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trialDiabetologia, 2013
- Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney diseaseDiabetes, Obesity and Metabolism, 2013
- Blood pressure‐lowering effects of GLP‐1 receptor agonists exenatide and liraglutide: a meta‐analysis of clinical trialsDiabetes, Obesity and Metabolism, 2013
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes, Obesity and Metabolism, 2013
- Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapiesJournal of the American Society of Hypertension, 2012
- Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trialInternational Journal of Clinical Practice, 2012
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trialDiabetes, Obesity and Metabolism, 2011
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Understanding heterogeneity in meta-analysis: the role of meta-regressionInternational Journal of Clinical Practice, 2009
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986